Finally, we showed that combining WEE1 inhibition with dynamic BH3 profiling represents an educated approach to guided therapy, and may lead to novel strategies in optimalized/personalized treatment selection in DLBCL patients. The gene discussed is WEE1; the disease is diffuse large B-cell lymphoma.